These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15640652)

  • 21. Clinical expert round table discussion (session 5) at the Margaux Conference on Critical Illness: outcomes of clinical trials in sepsis: lessons learned.
    Vincent JL; Angus D; Annane D; Bernard G; Faist E; Giroir B; Reinhart K
    Crit Care Med; 2001 Jul; 29(7 Suppl):S136-7. PubMed ID: 11445749
    [No Abstract]   [Full Text] [Related]  

  • 22. [Therapy concepts for septic diseases].
    Wildenauer R; Germer CT
    Chirurg; 2010 May; 81(5):477-8; author reply 478-9. PubMed ID: 20461351
    [No Abstract]   [Full Text] [Related]  

  • 23. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anticytokine therapy in sepsis and why it fails].
    Chýlek V; Kula R; Holub M; Szturz P; Sklienka P; Máca J
    Klin Mikrobiol Infekc Lek; 2008 Dec; 14(6):209-12. PubMed ID: 19214954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy of sepsis: why have we made such little progress?
    Teplick R; Rubin R
    Crit Care Med; 1999 Aug; 27(8):1682-3. PubMed ID: 10470798
    [No Abstract]   [Full Text] [Related]  

  • 26. Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis.
    Stegenga ME; Vincent JL; Vail GM; Xie J; Haney DJ; Williams MD; Bernard GR; van der Poll T
    Crit Care Med; 2010 Feb; 38(2):539-45. PubMed ID: 19851093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ketamine delays mortality in an experimental model of hemorrhagic shock and subsequent sepsis.
    Shaked G; Grinberg G; Sufaro Y; Douvdevani A; Shapira Y; Artru A; Czeiger D
    Resuscitation; 2009 Aug; 80(8):935-9. PubMed ID: 19473743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL6 plasma concentrations in patients with sepsis receiving SLED and antibiotics: a predictor for survival.
    McGuire TR; Reardon NT; Bogard K; Plumb TJ; Bultsma CJ; Nissen SW; Fuller PD; Olsen KM
    In Vivo; 2014; 28(6):1131-4. PubMed ID: 25398811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned.
    Reinhart K; Karzai W
    Crit Care Med; 2001 Jul; 29(7 Suppl):S121-5. PubMed ID: 11445746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis.
    Kruger P; Bailey M; Bellomo R; Cooper DJ; Harward M; Higgins A; Howe B; Jones D; Joyce C; Kostner K; McNeil J; Nichol A; Roberts MS; Syres G; Venkatesh B;
    Am J Respir Crit Care Med; 2013 Apr; 187(7):743-50. PubMed ID: 23348980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-L-selectin antibody therapy does not worsen the postseptic course in a baboon model.
    Redl HR; Martin U; Khadem A; Pelinka LE; van Griensven M
    Crit Care; 2005; 9(6):R735-44. PubMed ID: 16356222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum tumor necrosis factor-alpha and interleukin-6 levels in neonatal sepsis.
    Kurtogglu S; Caksen H; Hallaç IK; Ustünbas HB; Uzüm K; Kiliç H
    Pediatr Emerg Care; 2003 Jun; 19(3):219-20. PubMed ID: 12813315
    [No Abstract]   [Full Text] [Related]  

  • 33. Cytokine blockade in sepsis--Are two better than one?
    Hotchkiss RS; Karl IE
    Crit Care Med; 2001 Mar; 29(3):671-2. PubMed ID: 11373443
    [No Abstract]   [Full Text] [Related]  

  • 34. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression.
    Riedemann NC; Neff TA; Guo RF; Bernacki KD; Laudes IJ; Sarma JV; Lambris JD; Ward PA
    J Immunol; 2003 Jan; 170(1):503-7. PubMed ID: 12496437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azithromycin acts as an immunomodulatory agent to suppress the expression of TREM-1 in Bacillus pyocyaneus-induced sepsis.
    Tong J; Liu ZC; Wang DX
    Immunol Lett; 2011 Aug; 138(2):137-43. PubMed ID: 21507332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of macrophage hyperactivity improves survival in a burn-sepsis model.
    O'Riordain MG; Collins KH; Pilz M; Saporoschetz IB; Mannick JA; Rodrick ML
    Arch Surg; 1992 Feb; 127(2):152-7; discussion 157-8. PubMed ID: 1540091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sepsis bundles: time for a nursing initiative?
    Papathanassoglou ED
    Nurs Crit Care; 2009; 14(4):162-5. PubMed ID: 19531032
    [No Abstract]   [Full Text] [Related]  

  • 38. [Non-antibiotic treatment of sepsis].
    Møller K; Kronborg G; Pedersen BK
    Ugeskr Laeger; 2000 May; 162(20):2872-5. PubMed ID: 10860425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A potential new therapy for sepsis: learning from experience.
    Burnham E; Moss M
    Crit Care Med; 2001 Mar; 29(3):690-1. PubMed ID: 11379545
    [No Abstract]   [Full Text] [Related]  

  • 40. Characterization, epitope identification and mechanisms of the anti-septic capacity of monoclonal antibodies against macrophage migration inhibitory factor.
    Zhang Y; Zeng X; Chen S; Zhang Z; Li P; Yi W; Huang H; Yao J; Li S; Hu C
    Int Immunopharmacol; 2011 Sep; 11(9):1333-40. PubMed ID: 21571101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.